Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 3, 2010, Pages

  Lamon, Brian D ^a   Upmacis, Rita K ^a   Deeb, Ruba S ^a   Koyuncu, Hilal ^a   Hajjar, David P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Mitogen activated protein kinase phosphatase; Signaling; Smooth muscle cells; Vascular inflammation

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NITRIC OXIDE; NITRITE; STRESS ACTIVATED PROTEIN KINASE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE;

ANIMAL CELL; AORTA MEDIA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; GENE DELETION; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; AORTA; CELL CULTURE; CYTOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TIME; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; BLOTTING, WESTERN; CELLS, CULTURED; CYCLOOXYGENASE 2; ENDOTHELIUM, VASCULAR; INFLAMMATION; INTERFERON-GAMMA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 77956708349     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00144.2010     Document Type: Article

References (57)

1. Ali K, Lund-Katz S, Lawson J, Phillips MC, Rader DJ. Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells. Atherosclerosis 196: 201-209, 2008.
2. Arejian M, Li Y, Anand-Srivastava MB. Nitric oxide attenuates the expression of natriuretic peptide receptor C and associated adenylyl cyclase signaling in aortic vascular smooth muscle cells: role of MAPK. Am J Physiol Heart Circ Physiol 296: H1859-H1867, 2009.
3. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19: 646-655, 1999.
4. iα protein and adenylyl cyclase signaling in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 294: H775-H784, 2008.
5. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102: 840-845, 2000.
6. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005.
7. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105: 1816-1823, 2002.
8. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39: 443-452, 2005.
9. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, Flavell RA. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 103: 2274-2279, 2006. (Pubitemid 43271660)
10. Chyu KY, Dimayuga P, Zhu J, Nilsson J, Kaul S, Shah PK, Cercek B. Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ Res 85: 1192-1198, 1999.
11. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 118: 161-180, 2008.
12. Cipollone F, Fazia M, Iezzi A, Ciabattoni G, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, De Luca M, Prontera C, Chiarelli F, Cuccurullo F, Mezzetti A. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 24: 1259-1265, 2004.
13. 2-dependent plaque instability. Circulation 104: 921-927, 2001.
14. 2 synthase-1 by peroxynitrite. J Lipid Res 47: 898-911, 2006.
15. Deeb RS, Lamon BD, Hajjar DP. Silent partner in blood vessel homeostasis? Pervasive role of nitric oxide in vascular disease. Curr Hypertens Rev 5: 273-282, 2009.
16. Deeb RS, Nuriel T, Gross SS. Untargeted discovery of nitric-oxide- modified proteins. In: Nitric Oxide: Biology and Pathobiology, edited by Ignarro LJ. San Diego: Elsevier, 2010, p. 327-390.
17. 2 synthase. J Lipid Res 43: 1718-1726, 2002.
18. 2 synthase nitration and suppresses eicosanoid production. Am J Pathol 168: 349-362, 2006.
19. Deeb RS, Upmacis RK, Lamon BD, Gross SS, Hajjar DP. Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. Hypertension 51: 1-7, 2008.
20. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 28: 812-819, 2008.
21. Gresele P, Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev 24: 148-168, 2006. (Pubitemid 46696922)
22. Haider A, Lee I, Grabarek J, Darzynkiewicz Z, Ferreri NR. Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation. Circulation 108: 1015-1021, 2003.
23. Haworth O, Buckley CD. Resolving the problem of persistence in the switch from acute to chronic inflammation. Proc Natl Acad Sci USA 104: 20647-20648, 2007.
24. Henrion D, Dechaux E, Dowell FJ, Maclour J, Samuel JL, Levy BI, Michel JB. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. Br J Pharmacol 121: 83-90, 1997.
25. Jacob A, Molkentin JD, Smolenski A, Lohmann SM, Begum N. Insulin inhibits PDGF-directed VSMC migration via NO/cGMP increase of MKP-1 and its inactivation of MAPKs. Am J Physiol Cell Physiol 283: C704-C713, 2002. (Pubitemid 34920303)
26. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310: 1966-1970, 2005.
27. Komalavilas P, Shah PK, Jo H, Lincoln TM. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 274: 34301-34309, 1999.
28. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103: 3099-3104, 2001.
29. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases - regulating the immune response. Nat Rev Immunol 7: 202-212, 2007. (Pubitemid 46310479)
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
31. Mbonye UR, Yuan C, Harris CE, Sidhu RS, Song I, Arakawa T, Smith WL. Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 283: 8611-8623, 2008.
32. McClelland S, Gawaz M, Kennerknecht E, Konrad CS, Sauer S, Schuerzinger K, Massberg S, Fitzgerald DJ, Belton O. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 202: 84-91, 2009.
33. Metzler B, Li C, Hu Y, Sturm G, Ghaffari-Tabrizi N, Xu Q. LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19: 1862-1871, 1999.
34. Miyoshi T, Li Y, Shih DM, Wang X, Laubach VE, Matsumoto AH, Helm GA, Lusis AJ, Shi W. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice. Life Sci 79: 525-531, 2006.
35. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100: 2417-2423, 1997. (Pubitemid 27514879)
36. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 270: 14214-14219, 1995.
37. Perez-Sala D, Lamas S. Regulation of cyclooxygenase-2 expression by nitric oxide in cells. Antioxid Redox Signal 3: 231-248, 2001.
38. Pritchard KA Jr, O'Banion MK, Miano JM, Vlasic N, Bhatia UG, Young DA, Stemerman MB. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem 269: 8504-8509, 1994.
39. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69: S30-S37, 1993. (Pubitemid 23035604)
40. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007.
41. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci USA 102: 13147-13152, 2005.
42. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291, 1999.
43. Seta F, Chung AD, Turner PV, Mewburn JD, Yu Y, Funk CD. Renal and cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul Integr Comp Physiol 296: R1751-R1760, 2009.
44. Shears LL, Kawaharada N, Tzeng E, Billiar TR, Watkins SC, Kovesdi I, Lizonova A, Pham SM. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 100: 2035-2042, 1997. (Pubitemid 27459358)
45. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104-2113, 2008.
46. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78: 539-552, 2009.
47. Trostchansky A, O'Donnell VB, Goodwin DC, Landino LM, Marnett LJ, Radi R, Rubbo H. Interactions between nitric oxide and peroxynitrite during prostaglandin endoperoxide H synthase-1 catalysis: a free radical mechanism of inactivation. Free Radic Biol Med 42: 1029-1038, 2007.
48. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38: 1654-1661, 2006.
49. Upmacis RK, Deeb RS, Resnick MJ, Lindenbaum R, Gamss C, Mittar D, Hajjar DP. Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells. Am J Physiol Cell Physiol 286: C1271-C1280, 2004.
50. Vinals M, Martinez-Gonzalez J, Badimon L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol 19: 2405-2411, 1999. (Pubitemid 29477842)
51. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 17: 2479-2488, 1997.
52. Xie L, Hattori Y, Tume N, Gross SS. The preferred source of arginine for high-output nitric oxide synthesis in blood vessels. Semin Perinatol 24: 42-45, 2000.
53. Young W, Mahboubi K, Haider A, Li I, Ferreri NR. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 86: 906-914, 2000. (Pubitemid 30246989)
54. Zhang GX, Kimura S, Murao K, Shimizu J, Matsuyoshi H, Takaki M. Role of neuronal NO synthase in regulating vascular superoxide levels and mitogen-activated protein kinase phosphorylation. Cardiovasc Res 81: 389-399, 2009.
55. Zhang GX, Nagai Y, Nakagawa T, Miyanaka H, Fujisawa Y, Nishiyama A, Izuishi K, Ohmori K, Kimura S. Involvement of endogenous nitric oxide in angiotensin II-induced activation of vascular mitogen-activated protein kinases. Am J Physiol Heart Circ Physiol 293: H2403-H2408, 2007.
56. Zhang R, Bai YG, Lin LJ, Bao JX, Zhang YY, Tang H, Cheng JH, Jia GL, Ren XL, Ma J. Blockade of AT1 receptor partially restores vasoreactivity, NOS expression, and superoxide levels in cerebral and carotid arteries of hindlimb unweighting rats. J Appl Physiol 106: 251-258, 2009.
57. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 378: 707-713, 1997.